LTFS
BBIO icon

Ladenburg Thalmann Financial Services’s BridgeBio Pharma BBIO Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$29K Hold
830
– – ﹤0.01% 3900
2019
Q3 		$18K Buy
+830
New +$23K ﹤0.01% 4096

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Ladenburg Thalmann Financial Services's BBIO Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services held its BridgeBio Pharma (BBIO) position steady in Q4 2019 at 830 shares worth $29K. The position accounts for ﹤0.01% of the portfolio, ranked #3900.

Ladenburg Thalmann Financial Services first reported a position in BBIO in Q3 2019 and has held it in 2 quarters since. 88 funds tracked by Wall St. Rank hold BBIO as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 830 shares of BridgeBio Pharma worth $29K as of Q4 2019.
  • Ladenburg Thalmann Financial Services left its BridgeBio Pharma share count unchanged in Q4 2019.
  • BridgeBio Pharma made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #3900 holding.
  • Ladenburg Thalmann Financial Services first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 2 quarters since.
  • 88 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.